Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 10/20 | 0.53 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918982 | 0.90 | KCNH2 (0.52) | KCNH2CYP2C8 | |
| SCHEMBL243503 | 0.87 | KCNH2 (0.50) | KCNH2CYP2C8 | |
| SCHEMBL253936 | 0.83 | KCNH2 (0.47) | KCNH2CYP2C8 | |
| SCHEMBL1918655 | 0.75 | ANO1 (0.44) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL20088254 | 0.75 | KCNH2 (0.85) | KCNH2ALDH1A1 | |
| SCHEMBL2843988 | 0.75 | RAB9A (0.69) | KDM4EALDH1A1HSD17B10 | |
| SCHEMBL2836706 | 0.74 | KDM4E (0.44) | KCNH2KDM4EALDH1A1HSD17B10 | |
| SCHEMBL20088205 | 0.74 | KCNH2 (0.68) | KCNH2ALDH1A1 | |
| SCHEMBL14217294 | 0.74 | ABCB1 (0.43) | KCNH2CYP2C8KDM4EALDH1A1 | |
| SCHEMBL9948040 | 0.73 | ANO1 (0.42) | KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-9738653-B2 | Fused furans for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-28 | — | — | US | disclosed |
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024103-A1 | FUSED FURANS FOR THE TREATMENT OF HEPATITIS C | HAVCR2, HCCS, GOT1 | KCNH2 3442/4885CYP2C8 48/4885KDM4E 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.